The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models

Bibliografische gegevens
Hoofdauteurs:	Ford, D, Robins, JM, Petersen, ML, Gibb, DM, Gilks, CF, Mugyenyi, P, Grosskurth, H, Hakim, J, Katabira, E, Babiker, A, Walker, A
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Oxford University Press 2015

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
door: Ford, D, et al.
Gepubliceerd in: (2015)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
door: Walker, A, et al.
Gepubliceerd in: (2010)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
door: Gomo, Z, et al.
Gepubliceerd in: (2014)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
door: Ssali, F, et al.
Gepubliceerd in: (2006)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
door: Munderi, P, et al.
Gepubliceerd in: (2010)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
door: Walker, A, et al.
Gepubliceerd in: (2012)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
door: Gilks, C, et al.
Gepubliceerd in: (2013)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
door: Lara, A, et al.
Gepubliceerd in: (2012)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
door: Mugyenyi, P, et al.
Gepubliceerd in: (2010)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
door: Antonieta Medina Lara, et al.
Gepubliceerd in: (2012-01-01)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
door: Stöhr, W, et al.
Gepubliceerd in: (2011)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
door: Kityo, C, et al.
Gepubliceerd in: (2014)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
door: Ross, LL, et al.
Gepubliceerd in: (2019)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
door: Reid, A, et al.
Gepubliceerd in: (2008)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
door: Muyingo, S, et al.
Gepubliceerd in: (2008)

DART and laboratory monitoring of HIV treatment Reply
door: Walker, A, et al.
Gepubliceerd in: (2010)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
door: Kikaire, B, et al.
Gepubliceerd in: (2007)

Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.
door: Steven Baveewo, et al.
Gepubliceerd in: (2011-01-01)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
door: Cissy Kityo, et al.
Gepubliceerd in: (2014-01-01)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
door: Farmer, R, et al.
Gepubliceerd in: (2020)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
door: Bwakura-Dangarembizi, M, et al.
Gepubliceerd in: (2015)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
door: Crook, A, et al.
Gepubliceerd in: (2016)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
door: Lisa L Ross, et al.
Gepubliceerd in: (2019-01-01)

Monitoring of highly active antiretroviral therapy in HIV infection.
door: Walker, A, et al.
Gepubliceerd in: (2011)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
door: Szubert, A, et al.
Gepubliceerd in: (2015)

Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.
door: Lewis, J, et al.
Gepubliceerd in: (2012)

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
door: Aboulker, J, et al.
Gepubliceerd in: (2004)

Antiretroviral regimens for preventing HIV infection in infants
door: René E. Ekpini, et al.
Gepubliceerd in: (2005-07-01)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
door: Hakim, J, et al.
Gepubliceerd in: (2017)

Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
door: Lewis, J, et al.
Gepubliceerd in: (2017)

Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy.
door: Ruth E Farmer, et al.
Gepubliceerd in: (2020-01-01)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
door: Kekitiinwa, A, et al.
Gepubliceerd in: (2017)

Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.
door: Phillips, A, et al.
Gepubliceerd in: (2004)

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
door: Llibre JM, et al.
Gepubliceerd in: (2013-05-01)

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
door: Kiwuwa-Muyingo, S, et al.
Gepubliceerd in: (2012)

The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda
door: Odere Mathew, et al.
Gepubliceerd in: (2009-07-01)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
door: Prendergast, A, et al.
Gepubliceerd in: (2016)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
door: Gibb, D, et al.
Gepubliceerd in: (2002)

Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.
door: Ewings, F, et al.
Gepubliceerd in: (2014)

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.
door: Walker, A, et al.
Gepubliceerd in: (2007)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models

Gelijkaardige items

Gelijkaardige items